Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective

Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective

The advent of anti-HER2 targeted therapies has dramatically improved the outcome of HER2-positive breast cancer; however, resistance to treatment in the metastatic setting remains a challenge, highlighting the need for novel therapies. The arrival of new treatment options and clinical trials examini...

Full description

Bibliographic Details
Main Authors:	Cristiano Ferrario, Anna Christofides, Anil Abraham Joy, Kara Laing, Karen Gelmon, Christine Brezden-Masley
Format:	Article
Language:	English
Published:	MDPI AG 2022-04-01
Series:	Current Oncology
Subjects:	breast cancer HER2 oncology human epidermal growth factor receptor 2
Online Access:	https://www.mdpi.com/1718-7729/29/4/222

Similar Items

Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain
by: Daniel Rayson, et al.
Published: (2022-12-01)

HER2-low metastases of HER2-negative primary tumors: a single institution analysis of intertumoral and internodal heterogeneity in node-positive breast cancer
by: Ulrika Pellas, et al.
Published: (2023-07-01)

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting
by: Mita Manna, et al.
Published: (2024-10-01)

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
by: Satomi Watanabe, et al.
Published: (2019-03-01)

Actein Inhibits Tumor Growth and Metastasis in HER2-Positive Breast Tumor Bearing Mice via Suppressing AKT/mTOR and Ras/Raf/MAPK Signaling Pathways
by: Xiao-Xiao Wu, et al.
Published: (2020-05-01)

High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patients
by: Kåre Nielsen, et al.
Published: (2023-11-01)

HR+/HER2– Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review
by: Katarzyna J. Jerzak, et al.
Published: (2023-06-01)

Gallbladder Adenocarcinoma, Potential Target for Anti-Her-2 Therapy
by: Ghazi Zafar, et al.
Published: (2020-08-01)

Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases
by: Xiaoping Ma, et al.
Published: (2022-12-01)

Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis
by: Shuhui You, et al.
Published: (2023-12-01)

Mammographic and contrast-enhanced spectral mammography imaging findings of HER2-positive cancers according to hormone receptor status
by: Hebatalla Elkassas, et al.
Published: (2022-12-01)

Prognostic impact of reduced HER2 protein expression in post-neoadjuvant therapy resection specimens: A single institution experience and review of the literature
by: Jan Paredes Mogica, et al.
Published: (2023-12-01)

Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis
by: Florence R. Wilson, et al.
Published: (2017-10-01)

Trastuzumab‐induced toxic epidermal necrolysis in a Her‐2‐positive metastatic breast cancer patient—A rare case report
by: Jannatul Ferdause, et al.
Published: (2024-07-01)

Using in vivo fluorescence lifetime imaging to detect HER2-positive tumors
by: Yasaman Ardeshirpour, et al.
Published: (2018-04-01)

Interaction between HER-2 and Hormone Receptors in Breast Cancer
by: Majid Moghadaszadeh, et al.
Published: (2010-12-01)

Interaction between HER-2 and Hormone Receptors in Breast Cancer
by: Majid Moghadaszadeh, et al.
Published: (2010-10-01)

A Comprehensive Review on the Role of Human Epidermal Growth Factor Receptor 2 (HER2) as a Biomarker in Extra-Mammary and Extra-Gastric Cancers
by: Fnu Amisha, et al.
Published: (2023-05-01)

Inetetamab in combination with rapamycin and chemotherapy for trastuzumab‐treated metastatic human epidermal growth factor receptor 2‐positive breast cancer with abnormal activation of PI3K/Akt/mTOR pathway
by: Aijuan Wang, et al.
Published: (2023-09-01)

HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
by: Laura Morsberger, et al.
Published: (2022-11-01)

Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) metastatic breast cancer: A review
by: Ran Ran, et al.
Published: (2022-12-01)

HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
by: Jeongmin Seo, et al.
Published: (2023-12-01)

Complete Cerebrospinal Fluid Response to T-DM1 in HER2 Positive Metastatic Breast Cancer: A Case Report
by: Francesca Zacchi, et al.
Published: (2023-03-01)

Associations between body mass index and hormonal receptor, HER2/neu receptor, as well as other clinical characteristics of breast cancer
by: Ahmed Qassim Hadi, et al.
Published: (2024-06-01)

HER2-Specific Peptide (LTVSPWY) and Antibody (Herceptin) Targeted Core Cross-Linked Micelles for Breast Cancer: A Comparative Study
by: Nazende Nur Bayram, et al.
Published: (2023-02-01)

Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis
by: Florence R. Wilson, et al.
Published: (2018-11-01)

Challenges and future of HER2-positive gastric cancer therapy
by: Chenzhe Ma, et al.
Published: (2023-01-01)

Lipidated Peptidomimetic Ligand-Functionalized HER2 Targeted Liposome as Nano-Carrier Designed for Doxorubicin Delivery in Cancer Therapy
by: Himgauri Naik, et al.
Published: (2021-03-01)

Comparison of Immunohistochemical Methods (IHC) and Fluorescent in Situ Hybridization (FISH) in the Detection of HER2 /Neu Gene in Kurdish Patients with Breast Cancer in Western Iran
by: Mozaffar Aznab, et al.
Published: (2022-10-01)

Quercetin inhibits truncated isoform of dopamine- and cAMP-regulated phosphoprotein as adjuvant treatment for trastuzumab therapy resistance in HER2-positive breast cancer
by: Han-Sheng Chang, et al.
Published: (2024-09-01)

The Receptor Tyrosine Kinase TrkA Is Increased and Targetable in HER2-Positive Breast Cancer
by: Nathan Griffin, et al.
Published: (2020-09-01)

Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective
by: Michelle Bradbury, et al.
Published: (2023-12-01)

Exploring Therapeutic Challenges in Patients with HER2-Positive Breast Cancer—A Single-Center Experience
by: Ramona Coca, et al.
Published: (2024-08-01)

A bibliometric analysis of HER2-positive breast cancer: 1987–2024
by: Sherlissa Ali-Thompson, et al.
Published: (2024-05-01)

HOW SHOULD BE THE SURGICAL APPROACH TO HER2 POSITIVE BREAST CANCER?
by: Can Atalay
Published: (2010-01-01)

Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer
by: Yuxin Mu, et al.
Published: (2023-12-01)

Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study)
by: Silvia Antolín Novoa, et al.
Published: (2023-01-01)

Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers
by: Atif Ali Hashmi, et al.
Published: (2018-08-01)

Analysis of the association of HER-2 low carcinomas and PAM50 assay in hormone receptor positive early-stage breast cancer
by: Santiago Terán, et al.
Published: (2023-10-01)

Review of the status of neoadjuvant therapy in HER2-positive breast cancer
by: Gavin P. Dowling, et al.
Published: (2023-01-01)